Croda
This article was originally published in The Rose Sheet
Executive Summary
Marine biotech company Aquapharm Biodiscovery Ltd and ingredient supplier Croda International sign three-year deal giving Croda exclusive license to "novel marine-derived natural products identified through the collaboration from strains from Aquapharm's proprietary microbial library for use in topical cosmetic applications in skin and hair care," according to release. Croda will provide funding for Aquapharm to conduct research, along with royalties and milestone payments on commercialization of any resulting products. "The collaboration with Aquapharm is a key part of our strategy in developing novel, sustainable solutions for the personal-care industry," says Dr. Keith Layden, president of Croda...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.